Germline genetic testing has become an increasingly informative tool in the management of cancer patients. Over the past few years, the landscape of germline testing of prostate cancer patients has evolved significantly with the introduction of several multi-gene panel tests. Here, we dissect the clinically available prostate cancer-specific multi-gene panels and explore their performance on clinical series of prostate cancer patients from different ethnic groups.
You are browsing the legacy CJU website. The journal is now
published by Tech Science Press, and the latest issues, articles and
submission information are available on our new website.